Slides and Webcasts from all ESMO Preceptorships are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. ESMO thanks the authors for their generosity.
ESMO Preceptorship on Metastatic Bladder and Kidney Cancer 2024: Lugano
- Start date
- 03 Apr 2024
- End date
- 04 Apr 2024
- Location
- Lugano, Switzerland
Learning objectives
- To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer
- To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer
- To learn about advances in treatment and novel targets in bladder and kidney cancer
Accreditation
The programme of this event has been accredited with 10 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.
Co-Chairs
- Laurence Albiges, France
- Viktor Grünwald, Germany
Supported by
